Product Description
A novel, oral, systemically delivered LANCL2 agonist,for the treatment of rheumatoid arthritis (Sourced from: https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-announces-fda-clearance-its-ind-labp-104-0)
Mechanisms of Action: LANCL2 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NImmune Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Lupus Erythematosus, Systemic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
LABP-104-1a | P1 |
Completed |
Lupus Erythematosus, Systemic |
2022-04-28 |